We showed that our combination therapy led to stable disease in 60% of the patients and was associated with a median PFS time of 3.95 months, which was comparable with or better than those for other regimens as fourth‐line or later treatment of HER2‐negative breast cancer.31, 32, 33. This evidence concerns the gene ERBB2 and breast carcinoma.